CompanyRCKTNasdaqNew York, NY

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals develops genetic therapies for rare genetic diseases, focusing on AAV-based gene therapy for inherited cardiomyopathies and related disorders.

Stories only

SEC EDGAR ClinicalTrials.gov rocketpharma.com

8-KSep 15Latest SEC filing, period to Sep 15

Sep 15Latest story

September 2026

Rocket Pharmaceuticals says FDA aligns on Danon disease pivotal trial path

Sep 15Clinical readoutRocket Pharmaceuticals, Inc.

August 2026

Rocket Pharmaceuticals adopts new severance program, signs executive employment deals

Aug 27PeopleRocket Pharmaceuticals, Inc.

Rocket reports Danon safety clearance and $180M PRV sale in Q2 2026 update

Aug 10Quarterly updateRocket Pharmaceuticals, Inc.

June 2026

Rocket Pharmaceuticals names Joseph Manhede as principal accounting officer

Jun 30PeopleRocket Pharmaceuticals, Inc.